SEC-sourced researchBeta

RLAY

Relay Therapeutics, Inc.

US markets

Data passport

CIK: 0001812364
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Sep 9, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 12:03 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

RLAY · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	25,546,000.0000	Feb 26, 2026
December 2024	10,007,000.0000	Feb 26, 2026
December 2025	15,355,000.0000	Feb 26, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	15,355,000.0000	-276,479,000.0000	-235,455,000.0000	621,331,000.0000	54,271,000.0000	Feb 26, 2026
December 2024	10,007,000.0000	-337,708,000.0000	-249,107,000.0000	871,296,000.0000	93,504,000.0000	Feb 26, 2026
December 2023	25,546,000.0000	-341,973,000.0000	-300,316,000.0000	—	—	Feb 26, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$15.36M	December 2025	Feb 26, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$10.01M	December 2024	Feb 26, 2026	10-K
Net incomeNetIncomeLoss	-$276.48M	December 2025	Feb 26, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$235.46M	December 2025	Feb 26, 2026	10-K
Total assetsAssets	$621.33M	December 2025	Feb 26, 2026	10-K
Total liabilitiesLiabilities	$54.27M	December 2025	Feb 26, 2026	10-K

New filings

Explore methodology ↗